Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NMS-03305293 and Temozolomide in Recurrent Glioblastoma
NCT04910022Phase 2Active, not recruiting
- Sponsor
- Nerviano Medical Sciences
- Start
- Dec 2021
- Primary completion
- May 2027
- Modality
- Small Molecules
- Countries
- 5
01
Overview
A Phase 2 trial of itareparib in glioblastoma (GBM), Diffuse Glioma (DG), sponsored by Nerviano Medical Sciences. Started Dec 2021; status: active, not recruiting.
02
Drugs
itareparib
03
Conditions
glioblastoma (GBM)Diffuse Glioma (DG)
Beyond the preview
Go deeper on NCT04910022.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04910022.